EZH2 in normal and malignant hematopoiesis (Q34375614)

1 August 2017

EZH2 in normal and malignant hematopoiesis (English)

1 reference

1 August 2017

0 references

M Copland

3

0 references

author name string

K Lund

series ordinal

1

1 reference

PubMed ID

24097338

1 August 2017

P D Adams

series ordinal

2

1 reference

1 August 2017

7 October 2013

1 reference

1 August 2017

1 reference

1 August 2017

28

1 reference

1 August 2017

1

1 reference

1 August 2017

44-49

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2013.288

1 August 2017

0 references

cites work

The language of covalent histone modifications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Role of histone H3 lysine 27 methylation in Polycomb-group silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

The Polycomb group protein EZH2 directly controls DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Role of histone H2A ubiquitination in Polycomb silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Epigenetic control of hematopoietic stem cell aging the case of Ezh2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Epigenetic stem cell signature in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

MYC acts via the PTEN tumor suppressor to elicit autoregulation and genome-wide gene repression by activation of the Ezh2 methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

The polycomb group protein EZH2 is involved in progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

EZH2 mutational status predicts poor survival in myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Recent advances in acute myeloid leukemia stem cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.288

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

21 January 2018

1 reference

12 December 2020

Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing

1 reference

12 December 2020

Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring

1 reference

12 December 2020

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

1 reference

12 December 2020

The roles of EZH2 in cell lineage commitment.

1 reference

12 December 2020

Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity

1 reference

12 December 2020

Chromatin compaction by a polycomb group protein complex

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2013.288

1 reference

PubMed ID

24097338

Dimensions Publication ID

1 August 2017

0 references

1 reference

PubMed ID

24097338